
Eli Lilly's retatrutide doubles weight loss versus Ozempic in first head-to-head trial
Eli Lilly says patients taking its experimental obesity drug retatrutide lost roughly twice as much weight as those on Novo Nordisk's Ozempic in the first head-to-head trial of the two drugs, results announced on Wednesday alongside plans to seek US approval in early 2027.



































